GKOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Glaukos Corp (GKOS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong growth trajectory, positive analyst sentiment, hedge fund buying, and improving financial performance make it a compelling investment opportunity despite the recent price pullback.
The MACD is positively expanding, indicating bullish momentum. RSI is neutral at 58.185, and moving averages are converging, suggesting consolidation. The stock is trading near its resistance level (R1: 108.601), with key support at 103.154. Overall, the technical indicators show a stable trend with potential for upward movement.
Analysts have raised price targets significantly, with targets ranging from $127 to $160, citing strong growth potential in iDose and Epioxa.
Hedge funds have increased their buying activity by 318.02% over the last quarter.
Financials show robust revenue growth of 35.66% YoY and improved gross margin of 77.8%.
The company is still operating at a net loss (-$133.66M in Q4 2025), though the loss has narrowed significantly.
No recent news or congress trading data to provide additional sentiment or validation.
In Q4 2025, Glaukos reported a 35.66% YoY increase in revenue to $143.12M. Net income improved by 298.03% YoY to -$133.66M, and EPS rose by 286.67% YoY to -2.32. Gross margin increased to 77.8%, up 6.78% YoY, indicating improving operational efficiency.
Analysts are overwhelmingly positive, with multiple firms raising price targets and maintaining Buy or Overweight ratings. Key drivers include FDA approval for repeat dosing of iDose and strong growth expectations for Epioxa, with revenue acceleration projected for 2027 and beyond.
